Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Department of Rheumatology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Australas J Dermatol. 2022 Feb;63(1):e63-e66. doi: 10.1111/ajd.13752. Epub 2021 Nov 23.
For patients who do not achieve adequate disease control on biologic monotherapy, or monotherapy with an oral-systemic agent such as methotrexate, combination biologic therapy may be considered. To the best of our knowledge, we report the first case assessing the safety and efficacy of the combination of an interleukin-23 (IL-23) inhibitor (risankizumab) with a tumour necrosis factor-α (TNF-α) inhibitor (golimumab) in the treatment of psoriasis and psoriatic arthritis. After twelve months of treatment with risankizumab and golimumab, our patient experienced a significant improvement in his psoriasis and psoriatic arthritis without any adverse effects to date.
对于那些在接受生物单药治疗或甲氨蝶呤等口服全身药物单药治疗后未能达到充分疾病控制的患者，可以考虑联合生物治疗。据我们所知，我们报告了首例评估白细胞介素-23（IL-23）抑制剂（risankizumab）联合肿瘤坏死因子-α（TNF-α）抑制剂（golimumab）治疗银屑病和银屑病关节炎的安全性和疗效的病例。在接受 risankizumab 和 golimumab 治疗 12 个月后，我们的患者的银屑病和银屑病关节炎得到了显著改善，且迄今为止没有任何不良反应。
